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ABSTRACT
Senn, Kimberly. Evidence-Based Tuberculosis Screening and Testing Clinical Protocol
for Public Health and Primary Care Providers. Unpublished Doctor of Nursing
Practice capstone project, University of Northern Colorado, 2018.
Tuberculosis is a treatable and preventable disease; however, tuberculosis
continues to be a leading cause of morbidity and mortality around the globe. Per the
World Health Organization (2016), tuberculosis (TB) disease was responsible for 10.4
million illnesses and 1.8 million deaths in 2015. Strategic plans by public health entities
are continually under development at the global, national, and state levels to utilize
innovative methods for identifying, treating, and preventing transmission of TB. Newer
testing technologies and recommendations, are available for screening patients at risk for
developing TB disease, creating an opportunity for development of a new tuberculosis
screening and testing clinical protocol
The purpose of this project was to develop a point-of-care clinical protocol that
would assist public health workers and primary care providers with screening and testing
for tuberculosis. An online survey was developed to assess the effectiveness, efficiency,
and evidence-based content of the protocol. The protocol and survey were sent to 229
subject-matter experts for review and survey feedback. There were 25 responses to the
online survey. Overall, 79.6% of the participants thought the protocol was effective,
76.5% agreed it was efficient, and 85.2% stated it was evidence-based. Although the
response rate was low, respondents represented a variety of health disciplines, were
iii

experienced in TB screening, and provided specific feedback. The point-of-care
evidence-based screening and testing protocol has potential to provide effective and
efficient guidance in TB screening in public health, community health, and primary care
clinics.
Keywords: interferon gamma release assay, latent tuberculosis infection,
tuberculosis, tuberculosis testing, tuberculosis screening
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CHAPTER I
INTRODUCTION
New tuberculosis testing technologies have been introduced in the United States
within the past 15 years. Guidelines for interferon gamma release assay (IGRA) testing
for detection of mycobacterium tuberculosis were published by the Centers for Disease
Control (CDC) in the 2010 Morbidity and Mortality Weekly Report (MMWR; Mazurek et
al., 2010). In 2016, The U.S. Preventative Services Task Force (USPSTF) published its
final recommendation for tuberculosis screening of at-risk populations. In January 2017,
new clinical practice guidelines for diagnosing tuberculosis were published by the
American Thoracic Society and the CDC (Lewinsohn et al., 2017).
The other widely accepted test available to detect mycobacterium tuberculosis is
the tuberculin skin test (TST) developed by Von Pirquet and Mantoux in 1907-1908
(CDC, 1982). Given the original skin test is well over 100 years old, new developments
and technology to detect mycobacterium tuberculosis are long overdue. Treatment of
tuberculosis (TB) is becoming increasingly challenging as drug resistance is also on the
rise. It is imperative for providers to accurately diagnose and treat both latent and active
TB to avoid further increasing drug resistance, save limited healthcare resources, and
provide high quality care for patients. To accurately diagnose TB, it is important to
understand which test is best for the patient and how to interpret the results.
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In September 2016, the USPSTF finalized a recommendation statement for latent
tuberculosis screening. A grade B was assigned for screening populations at increased
risk of latent tuberculosis infection. Grade B means there is great certainty of a moderate
to substantial net benefit and screening at-risk populations is recommended (USPSTF,
2016). An evidence report supporting the USPSTF recommendations was published in
2016 by Kahwati et al.
In January 2017, the most recent guidelines available for diagnosing tuberculosis
were published by the American Thoracic Society, Infectious Diseases Society of
America, Centers for Disease Control and Prevention, and Clinical Practice Guidelines
(Lewinsohn et al., 2017). These recommended guidelines also supported screening
populations at risk for tuberculosis. Additionally, preferences for the IGRA test over TST
were established in most clinical situations. The exception to this was if the IGRA test
was too expensive, too burdensome, or not available. While these new guidelines did not
aim to impose a strict standard, they were meant to guide the clinician’s decision-making
based upon available evidence. Often many unique patient factors are associated with
clinical decision-making for TB screening and testing (Lewinsohn et al., 2017).
The purpose of this project was to design and implement a user-friendly clinical
protocol to assist providers in deciding which tuberculosis test would be most appropriate
based upon the patient’s clinical situation, risk factors, available financial resources, and
reason for screening. In addition, a decision-making tool was developed to assist
providers in determining clinical decision-making following positive, negative, or
indeterminate test results based upon the most current evidence-based guidelines for both
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the TST and the IGRA test. The most recent guidelines for TB diagnosis supported the
clinical protocol and decision-making tool (Lewinsohn et al., 2017).
Background and Significance
The United Nations Millennium Development Goals were committed to stopping
the TB epidemic by the end of 2015 through an initiative named the Stop TB Partnership.
This initiative was first developed in 2000. The efforts resulted in saving 43 million lives
between 2000-2014. Not all the objectives were met and progress toward TB elimination
showed a slow decline between 2000-2014 (Stop TB Partnership, 2015). Barriers were
identified that contributed to slow progression toward TB elimination: poor health
systems, poverty, malnutrition, migration, aging populations, smoking, and chronic health
conditions. There was also a lack of resources available to perform the optimal work
needed to fulfill the goal (Stop TB Partnership, 2015). In 2014, The World Health
Organization (2015a) created a renewed initiative called the End TB Strategy. This
updated initiative aimed to address barriers to progress previously identified.
Ending the TB epidemic requires identification of key populations most at risk for
developing TB disease. Medically underserved populations, individuals with increased
risk to TB exposure, and certain individuals who are immunocompromised due to certain
health issues and behaviors are at the highest risk. Target populations differ between
countries so it is the responsibility of each country to identify their own at-risk
populations. The updated initiative aims to treat 90% of the population with TB disease,
increase care for 90% of all vulnerable populations, and reach a 90% cure rate for all
people diagnosed with TB (Stop TB Partnership, 2015).
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Elimination of tuberculosis in the United States is dependent upon implementing
strategic plans to screen, test, and treat individuals at increased risk for developing active
TB disease. Screening and treatment of Latent TB Infection (LTBI) is the primary
method used for eliminating TB in the United States (Linas, Wong, Freedberg, &
Horsburgh, 2011). In both public health and primary care settings, it is important to
effectively screen for, test, and treat LTBI and active TB in a cost-effective manner. In the
most recent statement written by the USPSTF (2016), a moderate benefit of screening for
LTBI was noted in persons at increased risk for TB.
In addition to the TST, IGRA tests have been developed and are being used to test
for LTBI and TB disease. A wide variety of studies and literature have been published
assessing reliability, usefulness, and cost-effectiveness of both tests in many populations
at various risks for developing active TB (Linas et al, 2011). Few resources have been
found that compiled this information into a user-friendly, evidence-based, point-of-care,
clinical decision-making protocol applicable to all persons with various TB risk factors.
Populations at risk for tuberculosis include immigrants; refugees; foreign born
individuals from countries with a high prevalence of TB; immunocompromised
individuals including those with HIV, diabetes, and chronic health issues; people who are
homeless or in jail; individuals who inject drugs; and children and adults with recent
exposure to active TB disease (Horsburgh & Rubin, 2011). In addition to clearly
identifying who should be tested for TB, providers must choose which test to use--the
IGRA test or the TST. It is important for the provider and/or clinic staff to know how to
properly administer the test, interpret the results, and order additional diagnostic studies
to rule out active TB disease.
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Problem Statement
Resources and clinical guidelines are available to assist providers with clinical
decision-making regarding tuberculosis screening and testing. New guidelines for the
preferred use of the IGRA test in certain populations and situations were published by the
American Thoracic Society, Infectious Diseases Society of America, and Centers for
Disease Control (Lewinsohn et al., 2017). Several barriers were identified that
contributed to provider resistance to utilizing new testing techniques. One barrier
identified leading to potential challenges with clinical decision-making regarding TB
testing was a significant diversity in recommendations for IGRA testing in the literature.
Denkinger, Dheda, and Pai (2011) identified four different testing approaches in 33
different guidelines from 25 countries, the CDC, and American Academy of Pediatrics:
(a) a two-step approach using the TST first followed by the IGRA test; (b) IGRA test only
to replace the TST; (c) both the TST and the IGRA test together; and (d) either the TST or
the IGRA test but not both. With so many available choices for testing, providers might
be challenged with which diagnostic test to use given the patient’s clinical situation.
An additional challenge to clinical decision-making found in the literature was
many studies focused on testing specific populations at risk for TB. There were too many
unique patient situations and risk factors to rely specifically on any one guideline for
choosing the best TB diagnostic tool. Valuable clinic time could potentially be lost while
providers research best testing options for their patients. The Infectious Diseases Society
of America addressed this in its latest guidelines (Lewinsohn et al., 2017). Both the TST
and the IGRA are indirect tests with no ability to determine whether a patient has LTBI or
active TB disease. The test result itself provides limited information regarding next steps
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for the patient and this can be challenging to providers. The TST and IGRA sometimes
result in false positives. Newest recommendations by the Infectious Diseases Society of
America suggested considering confirmatory testing in situations when the patient being
tested is at low risk for TB and the initial test is positive (Lewinsohn et al., 2017). The
TST and the IGRA test do not distinguish active TB from latent TB. Further assessment
is needed in the form of symptom evaluation and chest radiograph in patients with
positive test results (Lewinsohn et al., 2017).
Gap Analysis and Opportunities
To move closer to TB elimination, it is important for providers to actively
participate in testing high risk individuals for TB. Currently, two types of approved tests
are available for determining exposure to TB: the TST and the IGRA. New evidencebased guidelines are available to assist providers in choosing who should be tested and
how testing should be done. Clinical decision-making needs to be streamlined into an
easy to access clinical tool to improve quality of care, effectiveness, and efficiency.
An opportunity exists to create a point-of-care clinical protocol for TB testing in
support of the most current evidence-based guidelines for providers to use. The goal of
this project was to improve the quality of patient care and clinical efficiency through an
easily accessible and user-friendly guide. The main objective in relationship to the goal
was to promote use of the best technology available for TB testing given a patient’s
unique clinical situation. The type of tool used for the clinical protocol was a decisionmaking clinical algorithm available in printed format.
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Population, Intervention, Comparison,
Outcome, and Time Question
For patients at high risk of TB disease presenting to the public health or primary
care clinic (P), will implementing a clinical protocol to assist providers with TB testing
decision-making (I) allow providers to choose the TB testing method that is most
effective, efficient, and evidence-based leading to accurate clinical decision-making and
proper identification of TB infection (O) at the time of the visit (T)?
Theoretical Framework
The Stetler (2001) model of research utilization was used to implement the new
clinical protocol and tool for TB testing. The Stetler model is a practitioner-based model
used as a guide to implement evidence-based research knowledge into practice. The type
of research utilization appropriate for this project was to use research to create a process
for routine problem-solving or clinical decision-making. The Stetler model contains a
series of steps that include critical-thinking and decision-making to facilitate use of
research findings. Criteria applicable to the studies include substantiating evidence,
current practice related to desire to change, fitness of the findings to the clinical setting,
and feasibility regarding risk compared to benefit. The assumptions of the Stetler model
include:
1.
2.
3.

4.
5.

The formal organization might or might not be involved in the individual’s
utilization of research.
Utilization might be instrumental, conceptual, and/or symbolic.
Other types of evidence and/or non-research related information are likely to
be combined with research findings to facilitate decision-making or problem
solving.
Internal and external factors can influence an individual’s or group’s view
and use of evidence.
Research and evaluation provide us with probabilistic information--not
absolutes.
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6.

Lack of knowledge and skills pertaining to research utilization and EBP can
inhibit appropriate and effective use. (Stetler, 2001, p. 7)

The Stetler (2001) model contains five phases. Phase I is preparation.
Preparation includes searching, collecting, and sorting research evidence and defining the
purpose and outcomes of the issue. Phase II is validation, which involves performing a
utilization-focused critique or synopsis of the issue. If the synopsis is accepted, Phase III
is the comparative evaluation/decision-making step. Phase III incorporates Phase II
findings into the setting, feasibility, substantiation of evidence, and current practice to
consider application. Phase IV is the translation/application step of the process and Phase
V is the evaluation phase (Stetler, 2001).
Literature Review
Several online databases were searched for research literature including Google
Scholar, Cochrane, CDC.gov, and the general University of Northern Colorado library
search engine. Search terms used for literature included interferon gamma release assay,
tuberculin skin test, latent tuberculosis infection, tuberculosis, tuberculosis testing and
tuberculosis screening. The terms recommendations and diagnosis of were also added to
these search terms to narrow the focus of the search for articles containing testing
recommendations and comparison of tests. More than 1,000 articles were scanned for
relevance to this project. An iterative search was also done from paper and electronic
references. A total of 19 articles were chosen for the literature review based upon five
different foci of information: evidence-based recommendations, test comparisons, clinical
decision support tools, discordant results, and effectiveness. A literature review table is
provided in Appendix A.
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Clinical Decision Support Tools
Only one article specifically addressed use of a clinical decision support tool for
TB screening; however, this clinical support tool did not address which test would be
most appropriate to choose given the patient’s risk. The tool was a computer-based
clinical decision support to alert the provider that testing was recommended (Steele et al.,
2005). The CDC (2016) provided many articles and provider resources that were helpful
for clinical decision-making for diagnosing TB including a mobile application for tablets
and smart phones.
Evidence-Based Recommendations
Three evidence-based recommendations published within the past 12 months
were utilized to create the clinical protocol. The Infectious Diseases Society of America
(IDSA) guideline for diagnosing TB in adults and children was the most recent
(Lewinsohn et al., 2017). The guideline recommended testing with the IGRA test over
the TST in most situations except for children under the age of five. The TST was also an
acceptable test if the IGRA was unavailable, too expensive, or too troublesome
(Lewinsohn et al., 2017). The USPSTF evidence report reviewed 72 studies and
determined both the TST and IGRA were sensitive and specific for TB in countries with
low TB burden like the United States (Kahwati et al., 2016). Pai and Menzies (2017)
offered TB recommendations for HIV-uninfected adults. This article and other associated
links in this article contained comparable recommendations to the IDSA and USPSTF.
Test Effectiveness
Seven test comparison studies are included in the literature review. The studies
compared the two commercially available IGRA tests--QFT and T-SPOT--with each other
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and/or the tuberculin skin test. Kobashi et al. (2008) evaluated differences between the
two commercially available blood tests for TB. Their study determined blood tests were
more useful than the TST in identifying patients with active TB disease. One study
compared TST with the QFT and Quantiferon-TB Gold test (QFT-G) and IGRA, resulting
in the QFT-G being slightly more specific than the TST in Navy recruits (Mazurek,
Zajdowicz et al., 2007). A study done by Manusco et al. (2012) determined an
insignificant statistical difference between the two commercially available IGRA tests
and the TST in U.S. military recruits. The two studies performed on military recruit
subjects in the United States provided valuable information for test choice since most
new military recruits are low risk for TB infection.
One study compared the TST with two commercially available IGRA tests in
individuals with suspected TB (Mazurek, Weis et al., 2007). In this study, all three tests
had similar sensitivity. Painter et al. (2013) compared the TST with QFT-G in immigrant
populations vaccinated with bacillus Calmette–Guérin (BCG) vaccine. The QFT-G
sensitivity was 86.4% compared with a TST sensitivity of 52.3% in this population. This
study confirms the preference for the IGRA test over the TST in persons with the BCG
vaccination. Another study compared two IGRA tests (Higuchi et al., 2008). This study
resulted in the T-SPOT test being more sensitive (100%) than the QFT-G (87.2%) but the
T-SPOT was less specific than the QFT at 83.3% and 98.8%, respectively (Higuchi et al.,
2008). A systematic review of IGRA tests in comparison to the TST for diagnosis of
active TB revealed the IGRA tests were more sensitive than the TST but not sensitive
enough to use IGRA tests to rule out a diagnosis of active TB (Sester et al., 2010).
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Diagnosing TB infection is challenging. Both IGRA tests and TST results might
be falsely positive, falsely negative, or indeterminate. Many factors influence discordant
results. Jeon et al. (2013) published a study that determined patients with high
inflammation markers such as C-reactive protein, immune compromised patients, or older
patients had a higher probability of indeterminate and false negative results with the QFTIn Tube Gold IGRA test. Another study reviewing literature from 33 different guidelines
in 25 countries showed much diversity in TST and IGRA testing recommendations
(Denkinger et al., 2011). This study recommended more transparent, evidence-based
guidelines for IGRA testing and noted a possible lack of disclosure of conflicts of interest
with the commercial IGRA tests. Lastly, a study was done regarding screening of Italian
healthcare workers for TB infection (Olivieri et al., 2016). Evidence in this study
supported use of the IGRA test to confirm positive TST tests in this population. The
newest IDSA (Lewinsohn et al., 2017) guidelines also provided recommendations for
considering additional confirmative testing with the IGRA after a positive TST in some
clinical situations.
Cost
Cost might be a contributing factor in test choice for some providers and clinics.
Review of literature using the search terms resulted in two appropriate research articles
containing information about testing specific high-risk populations with the IGRA test
and/or TST to determine cost-effectiveness. Pareek et al. (2012) conducted an
observational study and economic analysis of tuberculosis screening in 231 immigrants
using the TST and IGRA testing in the United Kingdom. Using the IGRA test in
immigrant populations might eliminate the need for a chest X-ray, which would improve
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cost effectiveness of using the IGRA test over the TST. Linas et al. (2011) indicated
screening in some groups was more cost effective using the IGRA test over the TST in
the United States. These groups included foreign-born persons, individuals at high risk
of TB reactivation, vulnerable populations (homeless, drug users, and prisoners), and
patients with medical co-morbidities such as diabetes. Data for this study were collected
through CDC surveillance data and National Health and Nutrition Examination Survey
estimates of positive TST prevalence (Linas et al., 2011). U.S. census population
estimates were used to determine equation variables. Life expectancy gains were
calculated comparing no screening at all with TST screening. Screening with the TST
resulted in a gain of 0.00-0.24 life months. In comparison to TST screening, IGRA
screening resulted in life expectancy gains of 0.00-0.01 life months (Linas et al., 2011).
Articles like these are useful in determining the most cost-effective test choice in
relationship to patient risk for disease.
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CHAPTER II
PROJECT DESCRIPTION
Project Objective
The objective for this project was to design and evaluate an easy to use clinical
protocol for future implementation in primary care, public health, and community health
clinics to assist clinicians with decision-making regarding the most effective, efficient,
and evidence-based testing methods for latent and active tuberculosis based upon the
patient’s identified risk factors for TB. To support decision-making, guidance on test
result interpretation and what to do if the results were indeterminate was provided. The
project assessed effectiveness and potential usefulness of the clinical protocol and, if
possible, assessed for improvements in properly screening and testing individuals at risk
for TB per evidence-based guidelines. This protocol included a clinical decision-making
algorithm, providing point of care assistance to health care providers.
Project Plan
The project was planned in five phases while incorporating the Stetler (2001)
model as a framework. Phase I was the preparation phase. Preparation for the project
included reviewing, collecting, and summarizing clinical evidence. A project site was
selected to provide expert advice in development of the clinical protocol. The optimal
site was one that focused on general TB prevention activities, especially in high-risk
populations. Populations at risk for tuberculosis per the CDC (Lewinsohn et al., 2017)
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definition included adults and children who were foreign-born, immunocompromised,
homeless, incarcerated, underserved, or had recent exposure to TB disease including
travelers potentially exposed to TB in countries where TB was prevalent. The clinic site
was also familiar with TB testing technologies including both tuberculin skin tests and
IGRA tests. It was important to receive acceptance from the chosen site in development
of the protocol and assessment of usefulness while avoiding disruption of staff daily work
flow.
Phase II involved developing the clinical protocol utilizing the review of literature
findings and expert opinions. Expert opinions were provided by the clinical site staff
experts along with experienced TB clinic providers and nurses. The protocol was
designed to enhance and complement current TB elimination objectives and assessment
tools already designed by the state health department.
Phase III was the process of distributing the TB testing protocol to volunteer
participants for review. Participants included TB experts and staff at local health
departments, community health clinics, and primary care providers. The tool was emailed to potential volunteer participants. The state TB program assisted with
distributing the protocol to volunteer participants.
Phase IV was the application phase of the project. A Qualtrics survey was
distributed to volunteer participants via e-mail. The survey consisted of three focus areas
that addressed components of the PICOT question. The first section assessed potential
clinical efficiency of the protocol while seeking feedback regarding the protocol design
and content. Another section sought information regarding current evidence-based
choices of tuberculin skin tests and IGRA blood tests. Information was sought regarding
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how use of the protocol would assist with evidence-based TB care. The survey also
assessed the provider’s perception of clinical efficiency and effectiveness including why
one test might be preferred over the other.
Phase V was the process of evaluating survey results. If results of the survey
revealed implementation of the protocol would improve clinical efficiency, effectiveness,
and success with evidence-based TB clinical decision-making, future implementation of
the protocol in clinical practice would be reasonable.
Congruence of Organization’s Strategic Plan to Project
The Colorado Department of Public Health and Environment (CDPHE; 2017)
provided guidance and recommended participants for protocol review. This project
supported the state health department’s strategic plan to eliminate TB. The project
committee consisted of one individual from the state health department along with two
university faculty members with interest in infectious disease control, public health,
and/or community health of patients in high risk populations.
Timeline of Project Phases
The project timeline was just over one year in length beginning with development
of the phenomenon of interest and ending with the final project defense. The project
began in January 2017 and ended in February 2018. The research committee was chosen
and the project proposal was written, proposed, and accepted by the end of spring
semester of 2017. During summer semester of 2017, the clinic site was assessed and
chosen for the pilot project. Development of the clinical protocol began during the
summer semester of 2017 with the objective of having the completely developed protocol
available by mid-June 2017. The project was implemented in October 2017. Final
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evaluation, completion, and defense of the project were completed in February, 2018,
which was three months later than originally planned in the timeline. A copy of the
original timeline graph is provided in Appendix B.
Resources
The budget for development of the clinical protocol was minimal. The clinical
protocol was developed utilizing technology currently available to the student at no cost.
Evaluation of the project was conducted using Qualtrics software available through the
university for no additional cost. No expenses were anticipated for additional personnel
to assist with project development. The protocol and survey regarding the protocol were
sent to participants in an electronic format via an e-mail attachment for printing on-site at
the expense of the agency. A budget of $800.00 was planned for travel and printing
expenses, which were incurred by the Doctor of Nursing Practice (DNP) student.
Ethical Considerations
Prior to project implementation, approval was obtained from the University of
Northern Colorado’s Institutional Review Board (IRB) on September 21, 2017. An IRB
approved consent form was developed and sent out with the recruitment letter, protocol,
and link to the online survey. Participation in the survey constituted consent; therefore,
no signature was required (see Appendix C for the recruitment email, IRB approval letter,
and consent form). A statement of mutual agreement with the CDPHE was also
developed and signed by the project committee prior to project implementation (see
Appendix D).
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CHAPTER III
EVALUATION OF OBJECTIVES
The main objective was to design and evaluate a clinical-based protocol for
determining the most appropriate TB testing method to use for specific patients based
upon risk factors for having or acquiring TB and test feasibility. The protocol included
evidence-based guidance about how to interpret TB test results, what the next clinical
steps should be if the test was positive or negative, and what to do if a test was
indeterminate or borderline. It was important to evaluate the effectiveness of test choice
and clinical efficiency of the protocol. A Qualtrics survey (see Appendix E) was
administered to participants along with protocol distribution to include questions related
to usefulness of the protocol and evidence-based guidance related to TB test result
interpretation. Data collection through the survey revealed preference for choice of test,
if the guidance for test result management was helpful, and if use of the protocol
encouraged practices to follow evidence-based guidelines. The survey also assessed if
the protocol would be helpful and practical for use in clinical sites.
Evaluation of the DNP project included assessment of the protocol regarding its
helpfulness in decision-making. The literature review revealed recommendations for
preferred use of the IGRA test in some high-risk populations but it also revealed potential
barriers to use of IGRA testing. The survey assessed expert participants’ preferences of
test choice and why one test might be chosen over the other. Evaluation of the project is
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represented by Phase Five of the Stetler (2001) model of evidence-based practice (see
Figure 1).

Figure 1. Model of evidence-based practice (Stetler, 2001, p. 276).

Application of Evidence-Based Measures
The PICOT question served as a basis for project evaluation: For patients at high
risk of TB disease presenting to the public health or primary care clinic, (P) will
implementing a clinical protocol to assist providers with TB testing decision-making (I)
allow providers to choose the TB testing method that is most effective, efficient, and
evidence-based leading to accurate clinical decision-making and proper identification of
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TB infection (O) at the time of the visit (T)? Evaluation of the project focused on
answering all components of the clinical question. Evidence-based measures as
recommended in the most recent guidelines were the basis of all clinical guidance
provided in the protocol.
Method of Analysis
Analysis of the evaluation data was descriptive in nature. Data were organized
with a focus on answering specific parts of the PICOT question: effectiveness,
efficiency, and evidence-based. Both qualitative and quantitative data from the
participant surveys were analyzed. Analysis of the participant surveys regarding
usefulness and practicality of the clinical tool was done by providing a descriptive report
of the results obtained from the Qualtrics survey.
Conclusion
The battle to eliminate TB continues to be a priority around the globe. The
initiative to stop TB involves several objectives including use of evidence-based testing
techniques for diagnosing TB infection. Newer technologies in the form of two
commercially available IGRA tests are available for TB testing. Opportunities exist to
assist clinicians to make best evidence-based choices with well-designed point-of-care
clinical protocols. Information obtained from TB providers and staff about the clinical
protocol helped determine the usefulness, efficiency, effectiveness, and utilization of best
clinical evidence in TB testing techniques. There may be future opportunities to
implement the clinic protocol if the tool proves to be useful.
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CHAPTER IV

RESULTS

This chapter presents the results of the project including survey responses from
subject matter experts. The purpose of this project was to develop a TB clinical protocol
for future use in public and community health clinics. The protocol was designed to be
clinically efficient, effective, and evidence-based. Additionally, expert feedback was
received evaluating the efficiency, effectiveness, and evidence-based content. Case
examples were presented in the survey for participants to test the protocol as it would be
used in the clinical setting.
Although there were 25 total responses to the survey, not every participant
answered each question. Overall responses to the survey supported implementation of
the TB protocol in practice. A few participants felt too many barriers existed for the
protocol to be useful in practice. Many suggestions were provided to assist with
modifying the protocol for improved efficiency, effectiveness, and evidence-based
practice.
Responses to Survey Questions
The following paragraphs discuss the responses to each survey question including
support or lack of concurrence based upon recent evidence-based guidelines. Overall,
most subject matter experts agreed the protocol was effective, efficient, and evidencebased. Feedback received for suggested additions, omissions, and changes to the
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protocol pointed out several areas for improvement. The responses also suggested
changes that did not align with current evidence-based recommendations, leading to the
necessity for further research prior to implementing suggested edits.
Question One: Effectiveness of
Screening Tool
The first question sought to address the effectiveness of the TB screening tool,
testing protocol, and result guidelines. Of 22 responses, 68.2% of the survey participants
strongly agreed or agreed that the TB screening tool would be effective for
implementation in practice in their clinic. Approximately18.2% of the participants either
somewhat agreed or neither agreed or disagreed as to the effectiveness of the screening
tool. A small percentage of participants (4.6%) strongly disagreed with the effectiveness
of the screening tool.
There were 21 responses to Question #1 regarding the effectiveness of the TB
testing protocol. Most participants (80.9%) either strongly agreed, agreed, or somewhat
agreed that the TB testing protocol would increase effectiveness of TB testing in their
clinic. The remaining 19.1% of the participants neither agreed or disagreed, disagreed, or
strongly disagreed that the testing protocol would increase effectiveness of TB testing in
their clinic.
Of the 21 responses regarding the effectiveness of the TB test results guidelines,
76.2% strongly agreed, agreed, or somewhat agreed to the effectiveness of the guidelines
in their clinic setting and 23.8% of the participants neither agreed, disagreed, or strongly
disagreed that the test results guidelines would be effective for use in their clinic.
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Question Two: Protocol EvidenceBased?
Survey question #2 asked participants to determine if the TB screening tool,
testing protocol, and result guidelines were evidence-based. Of 22 responses, 85.5%
strongly agreed, agreed, or somewhat agreed the TB screening tool was evidence-based.
Only two participants (9.6%) somewhat disagreed or disagreed that the screening tool
was evidence-based. Similarly, 85% of the participants strongly agreed, agreed, or
somewhat agreed that both the TB testing protocol and results guidelines were evidence
based. No respondents strongly disagreed that the testing protocol and results guidelines
were evidence-based.
Question Three: Protocol Efficient?
Survey question #3 addressed the efficiency of the clinical protocol. Overall,
82.1% of the participants agreed the TB screening tool was efficient, 9.1% neither agreed
or disagreed, and 14.2% somewhat disagreed, disagreed, or strongly disagreed that the
TB screening tool would be efficient for clinical use. The TB testing protocol and TB
test result guidelines were tied at 76% strongly agreeing, agreeing, or somewhat agreeing
that these components of the protocol would be efficient for use in the clinic setting.
Question Four: Suggestions Regarding
Additional Information
Survey question #4 sought suggestions for additional information to be added to
the screening tool. This question collected qualitative data from participants through an
open text box for comments. A total of nine comments were received.
The first comment referred to the second screening question located on the
tuberculosis screening questionnaire: Russia seems more specific than necessary. The
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FSR such a Tajikistan, etc., would have similar risk. Wouldn't "countries in Asia and
Eastern Europe work?” The participant suggested limiting the question to include
countries in Asia and Eastern Europe. The screening question followed recommended
screening guidelines from the CDC (2016), which specifically refers to individuals from
Russia be recommended for TB testing. It would be worth considering changing the
question if the CDC recommends it in the future.
No additional changes were indicated in the second comment: Can’t think of
anything.
The third comment reflected the efficiency of the entire TB protocol: I think the
simplicity is part of its utility--we can always dig deeper as needed. The participant
understood the protocol provided a quick, point-of-care reference that could be further
expanded upon as necessary.
In response to the fourth comment (Suggest removing all of Latin America when
only BRAZIL is on any list of HBC. Makes everything else suspect), the CDC (2016)
recommended individuals from most countries in Latin America be tested for TB.
Twenty-two countries were listed on the World Health Organization’s (2015b) TB high
burden list: Afghanistan, Bangladesh, Brazil, Cambodia, China, DR Congo, Ethiopia,
India, Indonesia, Kenya, Mozambique, Myanmar, Nigeria, Pakistan, the Philippines,
Russian Federation, South Africa, Thailand, Uganda, UR Tanzania, Viet Nam, and
Zimbabwe. It was estimated in the year 2000 that 80% of new TB cases in the world
originated in these countries (World Health Organization, 2015b). It is true that Brazil is
the only Latin American country on the high burden list; however, the CDC still
recommends screening individuals from most Latin American countries. This protocol
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follows current CDC recommendations. A link is provided to view countries with high
TB burden for use as an additional reference.
The fifth comment suggested clarification to terminology used in the screening
guidelines:
Nothing to add. Needs more clarification however. Be sure to define terminology
consistently. For example, define "lived in country where TB disease is common"
consistently. Do you mean for one month or longer for all questions? Define
health care worker? IV drug use should be referred to as "persons who inject
drugs." Some persons should have serial testing if risk factors are still present,
not just if new risk factors.
Terminology in the screening guidelines was based upon CDC (2016) guidelines. It
would be helpful to provide a clearer definition of which countries experience TB more
commonly and who to test based upon how long an individual resides in the country.
Adding a precise definition for “health care worker” would be possible but would also
add to the complexity of the tool. It is possible to easily change the wording regarding IV
drug use to persons who inject drugs.
The sixth comment suggested assessing pregnancy or future planned pregnancy:
Is the person pregnant or planning to be pregnant? Asking if a person is pregnant or
planning to become pregnant is not currently a question recommended as part of the
screening tool according to CDC (2016) guidelines. Pregnancy might alter treatment
decisions but might not affect the outcome of test results. The tuberculin skin test and
IGRA are safe to administer to pregnant persons. Testing recommendations are available
for pregnant persons through the CDC website.
The seventh comment suggested testing contacts of active TB cases: Information
about testing contacts to actives, and the recommendation for testing as soon as possible
after exposure and the 8-10 week follow up testing. The process of testing contacts to
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active TB cases requires additional detailed information beyond what is currently
included in the protocol. Testing contacts to active cases of TB disease is important for
avoiding spread of disease in the population. Additional information regarding contact
testing for individuals exposed active TB disease would be a good addition to the
screening tool for providers participating in contact investigation testing.
The eighth comment was in response to updating testing information: QFT -Plus
information, possibly adding to TST interpretation that one of the problems with reading
of the test can be a very subjective. The QuantiFERON Gold-Plus is the newest
generation of IGRA test available by Qiagen corporation released in October 2017.
Updating the protocol to include the most up to date test is appropriate and would be
done prior to implementing the protocol in practice. The participant stated the TST
interpretation could be subjective so it would be important for clinical staff administering
and interpreting TST results to be properly trained to avoid inaccurate results. This is
stated in the protocol.
In response to the ninth comment (I would add the link for TST in 3D), an online
TST and IGRA test result interpreter is available for use free of charge. The tool was
developed by researchers from McGill University Health Center (n.d.) in Montreal,
Canada. The interpretation tool is supported by The Public Health Agency of Canada and
the Stop TB Partnership (McGill University Health Center, n.d.). The tool appears to be
easy to access and use. More research is needed to confirm whether this tool is evidencebased and recommended for use. Information about the TST/IGRA test result interpreter
is available directly from McGill University Health Center’s website:
The following tool estimates the risk of active tuberculosis for an individual with
a tuberculin skin test reaction of ≥5mm, based on his/her clinical profile. It is
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intended for adults tested with standard tuberculin (5 TU PPDS, or 2 TU RT-23)
and/or a commercial Interferon Gamma release assay (IGRA). (p.1)
Question Five: Recommendations for
Additions to Testing Protocol
Survey question #5 assessed recommendations for additions to the TB testing
protocol. Seven comments/suggestions were provided by respondents. The first response
suggested adding the IGRA test for individuals with a history of BCG vaccine and a
positive TST: A second test - IGRA is indicated for TST-positive individuals from
countries where BCG is used. Many false-positive TSTs can be identified by IGRA
testing. The IGRA test is preferred for individuals with a history of BCG vaccine as
indicated in the test selection protocol.
One comment suggested a more specific definition of risk for disease progression:
Needs more clarification however. For IGRA, define what is meant by "low or
intermediate risk of disease progression." Also, it is confusing to have "LTBI
testing is recommended" only under the IGRA column. Under table for
performing both TST and IGRA, make it clearer that left column (Initial test
negative) is likely referring to TST. Also, IGRA is used in children under five
years of age. Look up a few published studies about that.
Further definition of what is meant by low or intermediate risk of disease progression
would be a helpful addition to the protocol. Upon further investigation, it was difficult to
find an exact definition of “low or intermediate risk of disease progression.” The CDC
(2017) recommendations focused upon testing individuals at high risk for progression to
active TB disease:
Most U.S. TB cases are associated with reactivation of longstanding, untreated
latent TB infection. Testing for and treating latent TB infection in high-risk
populations is the most effective way to prevent TB disease. Although anyone can
get TB, some people have a higher risk of getting infected with TB germs, and
should get tested for TB infection. These groups include:
• People born in or who frequently travel to countries where TB disease is
common.
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•

People who currently, or used to, live in large group settings, such as
homeless shelters or prisons and jails where TB is more common.

•

Health care workers and others who work in places at high risk for TB
transmission, such as hospitals, homeless shelters, correctional facilities,
nursing homes, and residential homes for people living with HIV.

•

Someone who has spent time with a person who has infectious TB disease.

•

Others with weaker immune systems, such as those with certain health
conditions or taking certain medications, have a higher risk of developing
TB disease once infected. (p. 1)

It could be assumed that any group or individual not meeting the testing criteria might be
at a lower risk of disease progression.
The participant also thought there was some confusion with part of the table under
the IGRA testing section. The statement “LTBI testing is recommended” is listed in the
IGRA preferred test choice section of the test selection protocol. It is possible to clarify
this further by changing the phrase to “for any person recommended to receive LTBI
testing.” This same participant also suggested adding information to the algorithm better
explaining why testing with both TST and IGRA would be recommended. The
participant assumed the initial test was a TST. The chart does not assume the initial test
is a TST because there is a possibility that the initial negative test could be an IGRA.
There was support by at least one subject matter expert in favor of testing children
under age five with IGRA. The most current guidelines have not yet confirmed nor
adopted the IGRA test as recommended for children under age five at this time even
though it is accepted by some in practice based upon recent research studies. According
to Adams and Starke (2017),
There is insufficient evidence to support routine use of IGRAs in children <5
years for evaluation of TB infection in the absence of symptoms. Some experts
favor use of IGRAs to evaluate children ages 2 to 4, especially in the setting of
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BCG vaccination. Most experts do not favor IGRA use in children <2 years due to
insufficient data; TST is preferred in this age group. (Whom to test section)
Information about the QFT-Plus test was again recommended to be added to the
protocol in survey question # 5. As previously recommended, all components of the
protocol need to be updated to the most currently recommended approved IGRA test. It
is uncertain precisely what the following response to question #5 referring to “At our
agency, we also enter testing data for our patients into the TST” would be as
documentation of testing data would be specific to clinic policy. It would not be
necessary to add a recommendation for data entry in the protocol.
Question Six: Suggestions for Additions
To Result Guidelines
Six total comments were made suggesting additions to the TB result guidelines
section of the protocol. One participant recommended adding more information to the
protocol regarding false positive tests in U.S. healthcare workers: A bit more on false
positives. US health care workers are now low-risk for TB and most positives without
prior exposure are false positives. Adding more information regarding healthcare worker
risk for TB and potential false positive tests would require further investigation by the
provider. The TB result guidelines are designed to be a simple point-of-care tool. Links
to access additional information are provided. Other than updating the testing
information to reflect the new QFT-Plus test, the remainder of the subject matter experts
had no additional recommendations for additions to the TB result guidelines.
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Questions Seven, Eight, and Nine:
Omitting Information from
Protocol
Survey questions #7, #8, and #9 asked participants to suggest omissions from the
TB screening tool, testing protocol, and TB test result guidelines. Two suggestions were
offered for omissions from the screening tool. One participant suggested not
recommending screening all individuals with diabetes: I don’t think screening all
diabetics is indicated without TB exposure risk. Diabetes mellitus increases the risk for
progression from LTBI to active TB disease. According to the CDC (2000), it is
appropriate to test populations with diabetes for LTBI. Additionally, changes were
recommended for the TB test result guidelines to test all populations who recently arrived
from medium and high burden countries; one participant suggested not including
recommendations for testing populations from most Latin American countries since
Brazil is the only country listed as a high burden country: As noted ALL of Latin America
is not HBC only one country is on lists--BRAZIL. The entire protocol was developed with
the most currently available screening and testing guidelines from the CDC (2016). Most
participants had no suggestions for omitting information from the three sections of the
protocol.
Questions # 10, #11, and #12:
Case Examples
Questions #10, #11, and #12 provided three different case examples for
participants to review. Each case example represented a different clinical scenario for a
fictitious individual with risk factors for TB. The participants were asked to utilize the
TB protocol to determine whether the patient should be tested. It also asked which test
the participant would choose based upon what was offered in their clinic setting and why
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that specific test was chosen. Appendix E provides specific details regarding the case
examples.
For question #10, of 15 responses received, 14 chose IGRA as the test of choice.
This demonstrated accuracy and consistency with use of the protocol. Most participants
agreed the IGRA was a better test choice to avoid a potential false positive response with
the TST since the patient had a history of receiving the BCG vaccine. Interestingly, one
participant did not feel it was appropriate to utilize the protocol for answering the case
example question since the participants were already subject matter experts.
Of the 14 responses to the case example in question #11, six participants chose
the IGRA test, seven chose the TST, and one chose both. The protocol recommended
tuberculin skin testing for children under five years of age. Some clinicians chose to use
the IGRA based upon more recent recommendations to do so. As previously stated, there
are no current formal recommendations in favor of performing IGRA testing for children
under age five (Adams & Starke, 2017). If IGRA testing is recommended for children
under age five in the future, the protocol would need to be updated to reflect that
recommendation.
Thirteen total responses were given to the case example in question #12. The test
selection protocol stated the IGRA is the preferred test of choice assuming the individual
should be tested. A TST is also an acceptable test for individuals. Significant variations
existed in the participants’ test choice for this case example. It is possible more specific
information should have been added to the case study including country of travel and
whether baseline testing was done prior to travel. While there was no right or wrong
answer to this case example question, responses were sought to test use of the protocol.
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Clinical expertise and professional judgement were used as an adjunct to the tool in
answering this question by some participants rather than just answering the question
based upon the protocol’s recommendations. Two participants indicated either test might
be used but IGRA would be preferred over TST. Five total participants stated the IGRA
was the better test choice, while three participants would use the TST. One participant
choosing the TST also added he/she would send the patient for a chest x-ray in addition
to the TST. One participant would use both tests even though it was not indicated
initially for testing based upon the protocol. Two participants stated they would not test,
while one stated they would wait 8-10 weeks after travel before testing.
Questions #13 and 14: Usefulness of
Protocol in Public Health and
Community Health Settings
Questions #13 and #14 asked participants if they thought the protocol would be
useful in the public health and community health settings and to comment why or why
not. Sixteen total responses were received. Twelve agreed it would be useful and four
disagreed. Those agreeing the protocol would be useful stated the protocol would be
user-friendly in the clinic setting; the protocol is a clear guideline; it increases awareness
of TB prevalence and risk for progression; it is simple and easy to use; it works well for
rural clinics where TB testing is not done as frequently; and it reminds providers to think
about TB. Two participants mentioned cost and insurance coverage for IGRA testing
might affect the test choice, which would be a potential barrier to increasing appropriate
testing. Those who felt the protocol would not increase appropriate TB testing stated the
protocol was unorganized, inaccurate, and missing information; public health already has
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similar tools available; and it might not increase testing but might improve quality of
testing.
Questions #15 and #16: Usefulness of
Protocol in Primary Care Setting
Questions #15 and #16 asked about potential for increased appropriateness of TB
testing in the primary care setting. Of 16 total responses, 13 stated the protocol would
increase appropriate testing in the primary care clinic. Negative comments indicated the
tool was not well organized; it had inaccurate and missing information; it lacked
incentives; there was lack of knowledge and lack of properly trained staff; and providers
were hesitant to treat LTBI in primary care. One comment stated primary care settings
saw more patients with health insurance, which might affect how testing was done.
Comments in favor of increased appropriateness of testing in primary care included clear
guidance, concrete guidelines, increased awareness of TB and TB testing, ease of use,
standards for testing, clinical clarification, improved approach to testing, and served as a
reminder to assess for TB risk factors.
Questions #17, #18, and #19: Profession
of Experts, Work Settings, and
Experience with Tuberculosis
Screening and Testing
The purpose of questions #17, #18, and #19 were to collect demographic
information of the subject-matter experts. Professions (question #17) included registered
nurses, physicians, one medical assistant, a community health promoter, and
epidemiologists. As noted in the results section, all participants except one reported
working in public health departments and one participant reported working in a
community health clinic. Most participants had more than five years of TB clinical
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experience, confirming the participants had knowledge and training in TB clinical
activities.
Fifteen participants reported working in public health departments and one
worked in a community health clinic (question #18). The survey was sent out to public
health and community health agencies to seek expert opinion in reviewing the protocol.
Fourteen of 15 participants who answered question #19 had experience with TB
screening and testing. Six participants had five years or less of experience, nine had
more than five years of experience, and five had 10 years or more experience, thus
confirming the respondents were subject-matter experts.
Evaluation
The objective of this DNP project was to design and evaluate a clinical protocol
for TB screening and testing to be utilized at the point-of-care. Intended clinics for
utilization of the TB clinical protocol in the future included public health, community
health, and primary care clinics. The protocol was designed to aid in clinical decisionmaking that was efficient, effective, and evidence-based. It was important to include the
ability to identify risk factors for TB indicating need for testing, recommended test type,
and how to interpret test results. The objective was achieved as all desired elements were
included the clinical protocol, which was based upon the most recent testing guidelines
available.
Protocol information was categorized into three sections: tuberculosis screening
questionnaire and guidelines, a test selection protocol, and interpretation of test results;
although designed to be used together, they might also be used separately. The algorithm
created for test choice was a simple, easy-to use-chart. The algorithm could easily be
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updated to accommodate new recommendations and provider or clinic preferences, thus
accommodating individual needs for protocol organization.
Clinical experts in TB screening and testing evaluated the protocol and provided
feedback through an online Qualtrics survey (see Appendix E). An average of 79.6% of
the participants strongly agreed, agreed, or somewhat agreed the entire protocol including
all three sections was effective. The guidelines for interpreting results scored lowest in
effectiveness with 76.2% respondents agreeing. The strongest area of agreement was that
85% stated the entire protocol was evidence-based by strongly agreeing, agreeing, or
somewhat agreeing. Clinical efficiency scored the lowest overall with an average of
76.5% strongly agreeing, agreeing, or somewhat agreeing that the protocol was efficient
for clinical use.
The survey assessed recommended additions and omissions from the protocol by
the subject matter experts. Rationale for this evaluation supported potential protocol
modifications to improve efficiency, effectiveness, and evidence-based content. Each
recommendation was reviewed and responded to following the comments in the results
and outcomes section of this chapter. Comments were received seeking additional
clarification regarding geographic locations of birth country to assess risk for testing.
Additionally, suggestions were received to clarify and update terms and/or phrases
written in the protocol. Terminology used in the protocol was adopted from the most
current guidelines used in the United States from the CDC (2016) but could be easily
modified to meet the needs of individual clinics. One necessary update to the protocol
included the most recently approved IGRA test--the QFT-Plus. It was also recommended
that a link to the TST in 3D web site be added as a clinical tool for TB testing. This
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could be added to the protocol by clinics utilizing the tool. More research needs to be
done to evaluate the tool for evidence-based practicality.
The survey assessed validity of protocol effectiveness through three case example
questions. The case examples included different patient scenarios for participants to
review. Participants were asked whether testing was indicated and which test they would
choose based upon what their specific clinic would offer. The patient in the first case
study question was an adult with a history of BCG vaccination. All participants chose the
IGRA test as recommended in the protocol. This case study question validated the
protocol’s effectiveness.
The second case study was a child under age five. Many participants chose the
IGRA test rather than TST for this patient based upon recent literature available
supporting use of IGRA in this population. The protocol recommended use of TST in
children under age five, which was based upon most current evidence-based
recommendations. Perhaps recommendations in favor of testing children under age five
with IGRA will change in the future based upon more recent studies. While some
participants chose the TST as the protocol suggested, others felt the IGRA was preferred
and chose not to follow the protocol as written.
The third case example evaluated a college student with a recent history of travel.
It is important to note that more information needs to be added to this example including
exact geographic location of travel. It was assumed the student needed to be tested since
the student was exposed to a population with increased risk factors for acquiring TB
infection and disease. All but one participant stated the student should be tested and both
tests were chosen equally by the participants based upon what they would use in their
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clinics. This case study was accurate with the suggestions in the testing protocol, also
proving protocol effectiveness.
The survey also asked participants’ professional opinions about usefulness of the
survey in both public/community health and primary care practice settings. The purpose
of this question was to assess efficiency of use in the clinic setting and to seek
confirmation that the protocol was necessary. Most participants (75% and 81%,
respectively) stated the survey would be useful in both settings. Comments in favor of
usefulness included clear guidance and ease of use. Comments against the usefulness
included inorganized/inaccurate information and that tools like this were already being
used in the public health setting so it might be more useful in primary care.
Demographic information collected in the protocol evaluated the amount of TB
clinical experience and profession of the survey participants. It was important to gain
this information to confirm participants had some TB clinical knowledge and experience.
Eleven of the 16 participants had two or more years of TB clinical experience and five
participants had two years or less experience. Ten participants were registered nurses;
other participants included epidemiologists, physicians, medical assistants, and a
community health promoter. All participants worked in health departments or
community health clinics.
Key Facilitators
Successful outcomes for the development of an efficient, effective, and evidencebased TB clinical protocol depended upon this researcher’s ability to identify the
problem. For this project, a need to develop a user-friendly tool was identified and
supported through the literature review. The literature review revealed much information
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existed for clinical decision-making regarding TB screening and testing; however, a
simple point-of-care tool was not found. Thus, the literature review served as a key
facilitator for this DNP project.
Development of partnerships is one of five criteria necessary to meet the
outcomes of a successful doctoral nursing project (Waldrop, Caruso, Fuchs, & Hypes,
2014). Intraprofessional collaboration requires use of resources provided by nursing
faculty and clinical nurse staff (Moran, Burson, & Conrad, 2017). Nursing faculty
members served as a guide for this researcher while clinical nursing staff served as
subject matter experts in review and evaluation of the project. Interprofessional
collaboration outside the discipline included public health experts in epidemiology,
administration, physicians, and other clinical staff with experience in TB testing. Moran
et al. (2017) shared several models supportive of interprofessional collaboration and its
importance in improving healthcare outcomes. Interprofessional and intraprofessional
collaboration among the researcher, scholarly faculty at the University of Northern
Colorado, TB elimination work group, and the CDPHE (2017) was the main key
facilitator that made this objective achievable. The researcher collaborated with both
faculty and professionals having knowledge, expertise, and common goals related to TB
prevention activities.
In December 2016, the Volunteer TB Elimination Planning Task Force presented
a 10-year plan to eliminate tuberculosis in Colorado. This elimination plan served as a
facilitator for development of the TB clinical protocol. Six goals were developed along
with strategies and objectives to support elimination of TB statewide. Goal two
specifically addressed the need to test individuals at risk for TB. Activities related to
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development of a screening tool and standardizing use of IGRA testing. The task force
also sought to provide communication strategies with medical providers in the fifth goal.
The first objective for this goal was to “develop and implement a strategy promoting
clear and simple guidelines for screening, testing and treatment of TB infection”
(Volunteer TB Elimination Planning Task Force, 2016, p. 17). An activity for this
strategy was to facilitate implementation of the screening/risk assessment tool and
provide a toolkit to providers (Volunteer TB Elimination Planning Task Force, 2016).
The group had previously developed a screening and risk assessment tool; however, this
project expanded upon that tool by adding evidence-based information for use of IGRA
testing, appropriate test choice in the test selection protocol, and a set of guidelines for
test interpretation. This project could be used with all three sections together or
individual sections as needed for inclusion in a provider toolkit.
Recommendations for diagnosing TB in adults and children were introduced in
January 2017 by the American Thoracic Society, Infectious Diseases Society of America,
and The Centers for Disease Control and Prevention (Lewinsohn et al., 2017). This
served as a facilitator for developing the protocol testing recommendations. The
guidelines served as the most current information available for TB diagnosis and were
utilized in the clinical protocol. The new guidelines supported use of IGRA testing as a
standard of practice.
Use of the nursing process was another key facilitator to formulating and
developing the objective. The assessment phase of the nursing process expanded upon
information obtained in development of the identified need for developing the clinical
protocol. The TB elimination task force strategies were used to assist with defining the
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project objective. Diagnosis was the phase of the nursing process where data obtained
through the literature review assisted with developing the need for the protocol. The
planning phase included a significant amount of time developing ideas for creation of the
project. Evaluation of the project collected information from the survey results and
dissemination of the outcomes for future projects (Moran et al., 2017).
The Stetler (2001) model of research utilization served as the facilitator for the
objective by assisting with closing the gap between evidence-based research and practice
through transformation of research into practice. Similar but also different than the
nursing process, the Stetler model has five phases: preparation, validation, comparative
evaluation/decision making, translation/application, and evaluation. Chapter III
described how the Stetler model was used in more detail. The model was versatile for
protocol development.
Additional facilitators for meeting the objective included a minimal budget
beyond time invested by the student, slight to no risk for volunteer participants, and
easily obtainable technology for protocol and survey development. Without these
facilitators, project delays and complications would have been inevitable.
Key Barriers
The DNP proposal required revisions to create a practical project. The project
timeline was affected by the researcher’s need to revise the proposal frequently as the
project was designed. Initially, implementation of the project in the clinic setting was
planned. A decision was then made to change the project to an expert review of the
protocol with the possibly of future implementation in the clinic setting. This process
allowed the researcher to seek feedback from subject matter experts to determine the
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potential efficiency, effectiveness, and evidence-based content of the protocol. It also
allowed for recommended modifications to be made prior to future implementation in the
clinic setting. Additional revisions were made to the project, thus affecting timeliness
related to the newly published guidelines by the Infectious Diseases Society of America
in 2017 (Lewinsohn et al., 2017). Time delays were a key barrier during this process.
The literature review revealed an abundance of information available to providers
for TB screening and testing. Developing a comprehensive tool that was simple to use at
the point-of-care served as a challenge in meeting the objective. A few comments
received regarding additions to the protocol would have led to a longer, more
cumbersome protocol and a less efficient point-of-care guide. To proactively address this
concern, links were added to the protocol for the provider to look up additional
information if needed. One survey comment addressed this well: the provider may “dig
deeper” for additional resources as necessary.
The key barrier to protocol development was professional decisions might
overrule protocol as was proven in the case examples. Choices were made in the survey
case studies by some participants that differed from recommendations in the protocol.
Professional opinion beyond commonly available testing recommendations was used by
some clinicians. For example, one subject matter expert recommended reviewing more
recent studies for use of IGRA testing in children under age five. While evidence-based
studies might be available, the most recent CDC (2017) guidelines do not yet recommend
use of the IGRA in children under five.
Comments received from subject matter experts identified potential barriers for
use of the protocol beyond professional clinical decision-making. It was anticipated that
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cost would be a contributing factor in test choice during protocol development. While
cost was not directly discussed in the responses, patient insurance coverage might force
clinicians to choose one test over another even if it was not the most preferred test. Staff
must be properly trained to perform both the IGRA and TST, which could be a problem
for some clinics. Providers might not be aware of who to screen, were unfamiliar with
treatment for LTBI, or felt no incentive for screening and testing. These factors were not
key barriers for development of this protocol but could be potential barriers for success
with future clinical effectiveness and efficiency.
Finally, a key barrier in the collection of data was a low response rate to the
survey. The goal for survey responses was less than expected with 25 responses of 229
e-mail invitations to participate--a 10.9% participation rate. The survey was delivered on
October 18, 2017. The link to the survey remained open for more than three weeks until
November 10, 2017. A reminder e-mail for participation was sent on October 30, 2017.
For unknown reasons, only 15-16 subject matter experts answered most questions by the
end of the survey. More information would have been collected if everyone had
completed the survey.
Unintended Consequences
A positive unintended consequence of the project was the ability to participate in
an opportunity to partially meet objectives for the TB elimination plan in Colorado.
Once the problem statement was decided upon, the researcher contacted the state TB
epidemiologist to request advisement and support for the project (CDPHE, 2017).
Introduction to the Volunteer TB Elimination Planning Task Force (2016) and the TB
elimination plan were offered. Development of a project to align with the goals and
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objectives written in the TB elimination plan was an opportunity to bridge the scholarly
project with a tangible plan for public health prevention activities.
A negative unexpected consequence was the need to update the protocol prior to
implementation in practice. In October 2017 a newer version of the IGRA test was
introduced by Qiagen--the QFT-Plus. The protocol would need to be modified with the
latest approved tests prior to moving forward with future phases. Modifications to the
protocol are easily made but the protocol must continually be reviewed and updated as
changes are recommended. It would be important to identify practical ways to provide
updates as needed to providers utilizing the protocol.
Both positive and negative unintended consequences were received from subject
matter experts about accepting the protocol for clinical use. Most supported use of this
simple protocol in the clinic setting. Responses in favor of or against utilization of the
protocol were unknown prior to sending it out for review so a mostly favorable response
was truly a positive consequence for the project. One comment received created an idea
that simply having a TB screening and testing protocol available would raise TB
awareness by serving as a reminder to screen patients for TB risk factors and test patients
at risk for TB. Negative unintended consequences revealed potential barriers to future
implementation of the project. There was concern that staff might not be appropriately
trained in testing techniques and insurance might not cover preferred tests.
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CHAPTER V

RECOMMENDATIONS AND IMPLICATIONS
FOR PRACTICE

This chapter contains final recommendations and implications for practice.
Several key facilitators and key barriers contributed to successes and challenges of the
project development and outcomes. Recommendations are included in support of key
facilitators while potential solutions for key barriers are addressed along with
recommendations for identified unintended consequences of the project. Suggestions are
provided for ongoing evaluation of the clinical protocol beyond the conclusion of this
project. Additional settings for project application are discussed. Personal leadership
goals for the DNP graduate including how this doctoral nursing project met the essentials
of DNP education are provided in this chapter as well.
Recommendations
The problem statement identified issues contributing to provider challenges with
TB screening and testing including diversities amongst recommendations, the focus only
on specific populations, and unique patient situations in the literature. The opportunity
existed to create an evidence-based protocol for improved and efficient clinical decisionmaking at the point of care. Recommendations for the problem statement remained to
improve the quality of patient care and clinical efficiency with use of the TB protocol.
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The CDPHE (2017) TB program served as the lead supporting organization for
this project. The TB program manager was very supportive and was a connection to
subject matter experts statewide. Recommendations for the site include continued pursuit
toward TB elimination in Colorado by working toward meeting the objectives as written
in the strategic plan. Continued work with graduate students interested in TB prevention
might maintain momentum with the volunteer task force.
Key stakeholders were public health, community health, and primary care clinics
with access to patient populations at risk for latent TB infection and active disease.
Recommendations for key stakeholders are to implement this protocol in the clinic setting
to increase testing for populations at risk and increase awareness of the importance of TB
prevention.
The university setting offers a great opportunity for graduate nursing students to
bridge the gap between scholarly work and clinical practice. Many opportunities are
available for the DNP student interested in population health to create clinical protocols
for population health prevention activities including communicable diseases like TB.
Connections with organizations such as state health departments persuade the health and
safety of populations. It is recommended that schools of nursing encourage doctoral
students to reach out to these organizations in support of scholarly projects.
Recommendations for the DNP student would be to narrow the focus of the
project and consider how projects should be developed in phases over time. The original
plans included testing the protocol in the clinic setting but it would be best to receive
subject matter expert feedback prior to live testing in the clinic. Waiting to implement
the protocol for a future project is a good choice while offering the option to update and
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improve upon the protocol, which would lead to a greater chance of success in the
clinical setting.
Recommendations and implications for practice exist for key facilitators. The
scholarly literature review provided a baseline for identifying the opportunity to develop
the protocol. It is recommended that an ongoing literature review be conducted
throughout the process to ensure the project is up to date with the most current
information.
Collaboration with key stakeholders was an important facilitator for success when
developing and meeting the objective. Collaboration also facilitated success with current
and future phases of the project. Ongoing collaboration with the volunteer task force is
recommended to move forward with the next phase of the project. Members of the task
force are experts in the profession and have great influence in promoting TB awareness,
increasing screening and testing, and supporting recommendations.
The Stetler (2001) model of research utilization along with the nursing process
facilitated forward movement of the project while allowing for continuous evaluation and
flexibility for transformation. The Stetler model provided flexibility and supported
utilization of research into evidence-based practice. Preparation, validation, decisionmaking, translation/application, and evaluation might be either formal or informal in
nature. It is recommended that use of this model be continued as a guide for future work
on the project.
A minimal budget was planned for this project, which primarily involved the cost
of time spent by the DNP student. A larger budget that included costs of professional
assistance with survey development and providing an incentive might have resulted in a
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greater response to the survey. A greater number of responses might have led to
additional recommendations for the protocol. Moving forward, offering an incentive for
clinics and providers to test the protocol in practice is recommended. The incentive
might include a small gift of appreciation such as gift card or perhaps a meal could be
furnished to providers along with an educational session about use of the tool in practice.
Modern technology was a great facilitator for protocol development, online
surveys, and communication with stakeholders. In the future, it would be essential to
collaborate with computer professionals to add protocol access in electronic health
records. The paper format is useful during development but providers rely on electronic
devices for access to records and clinical resources. Integrating the protocol into
electronic health systems once it is implemented in the practice setting would increase
access at the point of care.
Recommendations for identified barriers to meeting the objective include
reducing time spent on revisions, reviewing literature regarding IGRA testing in children
under age five, adding more links for additional testing information, considering test cost
and insurance coverage, and identifying ways to improve survey participation. Time
spent revising the project was stretched out over several months, which led to research
advisors and the DNP student to refamiliarize themselves with the details over time.
Improvements with time management would lead to smoother flow with both proposal
writing and protocol development.
Interferon gamma release assay testing for children under the age of five is not
currently recommended; however, subject matter experts were relying on more recent
studies for clinical decision-making for TB testing. It would be recommended to conduct
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an additional literature review of the topic in anticipation of changes to future testing
recommendations for children under age five.
The protocol recommended use of tuberculin skin testing as an acceptable
alternative when IGRA is too costly. While insurance coverage and cost are factors in
test choice, the protocol addressed an acceptable alternative. No additional
recommendations are currently proposed so decisions will continue to be based upon
agreements made between the provider and patient given the patient’s unique situation.
Several factors were identified affecting survey response rates. A systematic
review by Fan and Yan (2010) examined challenges with web surveys contributing to
low response rates. Factors in survey development include survey content and
presentation. Factors in delivery include sampling error in that not all participants have
access to the survey, modes of delivery, design of the invitations, use of pre-notifications
and reminders, and incentives. Factors affecting completion response rates include
theories about decision to participate. Factors affecting response rates when returning the
survey include software product used and data safety (Fan & Yan, 2010). In taking a
closer look at the present survey, many participants started the survey but did not
complete all the questions. Based upon recommendations by Fan and Yan, future
surveys should involve expert design to maximize responses. Additionally, the survey
was sent to a large contact list with a lengthy invitation. Improvements to the invitation
design might improve response rates along with a pre-notification of the upcoming
protocol and survey. It is also important to consider potential issues such as technical
challenges limiting access to and receipt of the survey.
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Continued progress and success with the TB clinical protocol will be dependent
upon continued support by the Volunteer TB Elimination Planning Task Force (2016). It
would be important to align future phases of the project with the objectives and activities
identified by the organization’s strategic plan. As written in the plan’s executive
summary, TB control is challenging but new technologies are improving the way TB is
diagnosed and treated. Work must continue to support efforts toward TB elimination
(Volunteer TB Elimination Planning Task Force, 2016). Success with future protocol use
will be dependent upon general upkeep and maintenance with most recent testing
technology and evidence-based recommendations. A plan needs to be made to address
updates and method of delivery to providers.
The researcher recommends this project be continued. Next steps include clinical
updating of the protocol based upon expert recommendations and implementation at
point of care. Continued collaboration with the state health department and task force
would assist with locating volunteer settings for testing the protocol in the clinical setting.
Additionally, it will be important for providers to have electronic access to the protocol
so additional stakeholders must be added to the project for technological assistance.
Decisions will need to be made regarding who will be responsible for updating the
protocol in the future.
Ongoing Evaluations
Evaluating success of the clinical protocol in the practice setting will be important
beyond the scope of this DNP project. Clinicians and administrators will be responsible
for monitoring the effectiveness, efficiency, and evidence-based content of the protocol
in the practice setting. This might be done through data mining of electronic records at
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the clinical site to evaluate appropriate screening and testing of patients at risk for TB.
Clinics will need to develop goals, objectives, and activities to support such ongoing
evaluation. The TB elimination strategic plan has a goal to support tracking and
evaluation of programs to measure progress of integrating new technologies (Volunteer
TB Elimination Planning Task Force, 2016). Public health and community health
providers will be responsible for providing support, education, communication, and
disease monitoring at the population level in response to future phases of the project.
Recommendations for Project Application
in Other Settings
Any setting with populations at high-risk for TB would be able to utilize the
protocol. Correctional facilities, university health clinics, homeless shelters, and mobile
health vans providing care to underserved populations would be ideal settings for project
application beyond public health departments, community health centers, and primary
care clinics. These settings should be screening for and testing individuals for TB risk
factors. Public health authorities would be responsible for identifying settings with highrisk populations and providing education and toolkits for successful screening and testing
programs. The clinical protocol should be part of that toolkit.
Personal Leadership Goals
As a DNP graduate student, personal leadership goals included gaining the
knowledge and skills to bridge the gap between theory and clinical practice. The DNP
graduate program is designed for the student to successfully comprehend all the elements
of the scholarly project and assemble them into a final scholarly work designed for
practical use. The ultimate result of combining scholarly work with practice should
contribute to improvements in health care and increase knowledge in a specialty area
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(Moran et al., 2017). This project prepared the student to identify quality articles,
research best evidence for practice, identify an opportunity, and develop a project that
will improve population health care outcomes that align with current strategic plans.
It was important for this DNP graduate to provide leadership within
interprofessional teams. Experience gained with collaboration with university faculty,
public health, nursing, and primary care provided the skill set needed for leadership in an
advanced health care profession. The National Center for Healthcare Leadership (2017)
strives to improve health care through leadership and organizational excellence. Creating
collaboration was a main objective along with creating a base of evidence for optimizing
leadership in healthcare. Quality health care relies on the ability for professionals to
work together across many disciplines, which met this professional leadership goal.
Essentials of Doctor of Nursing Practice Education
Doctor of Nursing Practice education consists of eight essentials for doctoral
education developed by the American Association of Colleges of Nursing (AACN;
2006). The following section explains the eight essentials along with how this project
met each item.
Essential I: Scientific Underpinnings
for Practice
This essential expectation is best described by the DNP educated advanced
practice nurse when demonstrating understanding of complexities of practice. It is
important for the DNP student to effectively translate knowledge to practice.
Preparations for meeting this essential include integrating nursing science with a variety
of other sciences, use theory and concepts to improve health care delivery, and develop
new approaches to healthcare delivery through application of theory (AACN, 2006).
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Development of a new clinical protocol for TB screening and testing met the
requirements for this first essential. Knowledge regarding TB screening and testing was
obtained through combined nursing clinical experience and a review of literature. The
Stetler (2001) model was utilized to facilitate development of the evidence-based
protocol derived from the research findings in the literature review. Healthcare delivery
will be improved through use of this effective, efficient, and evidence-based project.
Essential II: Organizational and Systems
Leadership for Quality Improvement
and Systems Thinking
To best summarize this essential, DNP prepared graduates must understand
organizations and systems leadership to improve health outcomes in populations. This
essential extends beyond direct patient care into having the skills to work on strategies for
quality improvement in the health care setting (AACN, 2006). This scholarly project met
Essential II by the development of a protocol that not only assisted with clinical care
activities but also aligned with the strategic plan to eliminate TB in the population. The
population at risk for TB requires much sensitivity, working within a limited budget
(many volunteer hours from professionals), and excellent communication skills for
success.
Essential III: Clinical Scholarship and
Analytical Methods for EvidenceBased Practice
This essential is best summarized as successful application of scholarship into
practice. According to the AACN (2006), this also includes the ability to evaluate
practice, improve outcomes, and participate in research. The objective for this project
was to develop a useful protocol based upon research that was applicable to practice,
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which met Essential III. Additionally, a thorough evaluation of the protocol was
achieved through an online survey and collaboration with subject matter experts. The
protocol was designed to improve quality of care that was effective, efficient, and
evidence-based. Findings of the survey were intended to lead to developing a quality
product for use in practice.
Essential IV: Information Systems/
Technology and Patient Care
Technology for the Improvement and Transformation
of Health Care
This essential requires graduates to be proficient in the use of information systems
and technology. Five requirements are needed to meet the expectations: use of programs,
analyzation of health care information systems, ability and technical skills for data
extraction, leadership, and evaluation (AACN, 2006). Use of technology during
development of this project was abundant. Technology was used to obtain and evaluate
information. An online survey was used to collect and evaluate data. Communication
networks including e-mail and phone conferencing were used to attend regular meetings
to share and execute plans.
Essential V: Health Care Policy for
Advocacy in Health Care
Governmental involvement is important in creating, enforcing, and supporting
healthcare policy to deliver healthcare services. This essential required the DNP graduate
student to assume a leadership role on behalf of the public and the profession. Many
issues are involved with delivery of health care (AACN, 2006). Patients at risk for TB
are culturally diverse and many have additional healthcare disparities contributing to
increased risk. Healthcare policy greatly influences the way TB is prevented and
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controlled. As a volunteer on the task force for TB elimination in Colorado and as a
student willing to share the project with local government health agencies, the researcher
met the requirements for Essential V.
Essential VI: Interprofessional
Collaboration for Improving
Patient and Population
Health Outcomes
The DNP graduate must be able to work effectively with multiple disciplines and
exhibit appropriate leadership in teams (AACN, 2006). Communication and
collaboration with multiple teams was necessary for development of this protocol.
Epidemiologists, program managers, providers, nurses, university faculty, and outreach
workers were involved in providing feedback throughout the process. The researcher
provided leadership and guidance throughout the process by coordinating meetings and
providing updates to advisors.
Essential VII: Clinical Prevention and
Population Health for Improving the
Nation’s Health
Implementation of clinical prevention and population health activities summarizes
this essential (AACN, 2006). This DNP project was based upon goals to prevent and
eliminate TB from the population at the state level. The strategies for local population
health are a part of a greater strategy developed by the WHO (2015) to eliminate TB.
The DNP student extensively analyzed TB data as it related to population health and also
developed a protocol to assist with screening and testing high-risk populations for TB.
This project met the requirements of Essential VII.
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Essential VIII: Advanced Nursing
Practice
This essential requires the DNP graduate prepare for advanced practice in a
specialized area of nursing. It is important to note that the essential provides a foundation
for practice as a DNP. Essential VIII is a culmination of skills required by essentials I
through VII with application to practice. The DNP must be able to assess health and
illness in complex situations, provide therapeutic interventions, have therapeutic
relationships, demonstrate advanced levels of clinical judgement and thinking, support
and mentor other nurses, educate and guide others, and demonstrate strong analytical and
conceptual skills (AACN, 2006). This project aimed to design an evidence-based
protocol with the goal of improving outcomes for patients and the TB population.
Various clinical experiences in family practice were obtained throughout the program.
Additionally, specialty TB clinical knowledge, nursing knowledge, and advanced
analytical skills in population health issues were required to develop the TB protocol,
thus meeting the requirement for Essential VIII.
Summary
Clinical use of evidence-based tuberculosis testing technologies based upon
newer recommendations released by the USPSTF in 2016 and the Infectious Diseases
Society of America, Centers for Disease Control and Prevention and American Thoracic
Society (Lewinsohn et al., 2017) provided an opportunity to create a new efficient,
effective, and evidence-based TB screening and testing protocol. Goals to eliminate TB
both globally and locally supported increased screening and testing for individuals at high
risk of TB. Providers need assistance with clinical decision-making at the point-of-care
to encourage appropriate TB screening and testing. The Stetler (2001) model of research
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utilization served as a model to guide the project. Development of the protocol aligned
with the strategic plan to eliminate TB in Colorado (CDPHE, 2017). Once the protocol
was developed, expert feedback was received through a Qualtrics survey. Most
respondents agreed the protocol was efficient, effective and evidence-based. Respondent
comments were reviewed regarding recommended edits, omissions, and additions to the
protocol. Once the protocol is updated with the newest test and modified based upon
expert suggestions, it will be ready for testing in practice. This DNP project met the eight
essentials required of the DNP graduate.
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Year

Author, Title,
Journal

1995

Bloch, A. B.

2005

Steele et al.

2007

Mazurek, Weis et
al.

Purpose

Sample

Method

Results/other

N/A

N/A

Comparison of
TST, QFT, and
QFT-G in subjects
suspect for TB

148 subjects with
suspected TB

Provides CDC
recommendations
for identification of
and screening high
risk populations for
TB
Screening of high
risk patients for
LTBI increased from
8.9% to 25.2% with
the computerized
clinical decision
support tools which
included alerts and
guided web-based
documentation.
All 3 tests have
similar sensitivity in
subjects with culture
confirmed TB, but
negative tests should
not be used to
exclude diagnosis of
TB in patients with
symptoms of TB.

Prospective,
cross-sectional
comparison study

8463 patients in
Utilization of
two primary care, computerized
outpatient, public clinical tools
community
health care
clinics

All subjects were
tested with three
tests
simultaneously
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Design
(descriptive,
systematic
review,
observational,
etc.)
Recommendations Expert Opinion
for screening for
TB by the
advisory council
for the elimination
of tuberculosis
Determine impact Nonrandomized
of computerized
prospective
clinical decision- intervention study
making support
and guided webbased
documentation on
screening rates for
LTBI

2007

Mazurek,
Zajdowicz et al.

Comparison of
TST, QFT, and
TB-SPOT test in
Navy recruits

Cross-sectional
comparison study

856 Navy
Recruits

2008

Kobashi et al.

Study assessing
transitional
change of TB
blood test results
during TB
treatment

Comparison study

48 patients with
confirmed active
TB disease and
50 healthy
subjects

2009

Higuchi et al.

Comparison study

47 patients with
active TB and 84
healthy subjects

2010

Sester et al.

Comparison of
two TB blood
tests for
diagnosing TB
Review of IGRA
tests for
diagnosing active
TB

Systematic review 27 articles met
and meta-analysis inclusion criteria

Subjects were
tested with TST,
QFT, and QFT-G
for comparison
of results
TST, QFT-TB,
and T-SPOT test
were done, serial
testing was done
during treatment
of the active TB
subjects

QFT-G and Tspot were
administered to
each participant
PRISMA
And QUADAS
Guidelines

Specificity of QFTG (99.8%)and TST
(99.1%) were higher
than QFT (92.3%)
Both commercial
blood tests were
more useful than
TST for patients
with active TB, no
significant
differences between
the two tests, several
false negatives and
indeterminate tests
were found in 13%
of immune
compromised
subjects
T-SPOT sensitivity
was 100% and QFTG sensitivity was
87.2% in this study
Diagnostic
sensitivities for
IGRA are higher
than TST, but IGRA
should not be used
solely to rule out
active TB

65

2010

Mazerek et al.

Provide
recommendations
for use of IGRA

Expert opinion

N/A

Literature review

2011

Linas et al.

Identify cost
effective TB
screening tests
and estimate costs
of testing for both
TST’s and
IGRA’s

Comparison
Study

Subjects were
defined by CDC
risk groups for
TB, Data was
retrieved from a
large US
database, cost of
test varies by age
and risk factors

Cost analysis
utilizing Markov
model

2011

Denkinger et al.

Identify diversity
in TB testing
recommendations

Systematic
Review
and
Descriptive Study

33 guidelines
And
50 expert
consultations

Review of
evidence-based
guidelines and
expert opinions

Provides
recommendation for
use of IGRA-newer
guidelines have
since been published
This article is a
comparison study
between the TST
and IGRA tests
utilizing a Markov
model to determine
cost effectiveness of
both TB tests in
high risk
populations.
4 main approaches
to TB testing
recommendations
exist (2-step, IGRA
only, both TST and
IGRA, either TST or
IGRA-not both);
overall increased
use of IGRA’s but
current guidelines
are not objective or
transparent
(disclosing conflicts
of interest)
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2011

Horsburgh &
Rubin

Identify
candidates for TB
screening, select a
test, and choose a
treatment

N/A

Guidelines
review and
recommendation

2012

Mancuso et al.

Comparison of
diagnostic tests
for TB

Cross-sectional
comparison study
of 3 commercially
available tests

2,017 military
recruits

2013

Pareek et al.

Comparative
performance and
cost effectiveness
of IGRA tests and
TST test with and
without chest xray in UK

Comparison
Study

231 foreign-born
immigrants

Review of
evidence-based
guidelines

This article is a
review of current
TB testing/treatment
guidelines and
recommendations
based upon those
guidelines
Risk factor
In populations with
questionnaire and a low prevalence of
QFT-GIT, T-spot, TB, there is not
TST were given
much difference in
to each
specificities in any
participant
of the three tests.
TST (99.3%), QFTGIT (98.8%) and TSPOT(98.7%). 88
subjects had positive
tests, only 10 of
these were positive
to all three tests
Comparison and CXR could be
Cost analysis of
eliminated if IGRA
IGRA and TST
testing is used
test
which would be cost
effective in the
newly arriving
immigrant
population.
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2013

Jeon et al.

Study analyzing
factors that
contribute to
discordant TB test
results

Retrospective
study

2013

Painter et al.

Comparison study

2016

Olivieri et al.

Compare
sensitivity of QFT
and TST in
immigrant
population with
universal
vaccination with
BCG vaccine at
birth
Study of results of
IGRA test in
addition to TST in
Italian health care
workers

2016

USPSTF

Screening
recommendations
for adults at
increased risk for
tuberculosis

Recommendations N/A
based on review
of evidence

Retrospective
study of LTBI
screening
program

Analysis of
laboratory and
clinical data of
1301patients
diagnosed with
TB in Seoul,
Korea
996 Viet Nam
immigrants with
abnormal chest
x-ray and 479
immigrants with
normal chest xray

Analysis of
discordant test
results

2136 Italian
healthcare
workers

All subjects with
initial positive
TST test were
tested with QFTGIT along with a
group of TST
negative subjects
Grading of
testing
recommendations
for TB

QFT and TST
results were
obtained

In patients with high
inflammatory
markers like CRP, or
older age QFT-GIT
results may have
higher indeterminate
or negative results
QFT is just as
sensitive as TST in
detecting TB in this
population, fewer
chest x-rays were
necessary with QFT
making QFT
preferred test for
this population
Use of QFT-GIT test
as a second step is
useful for detecting
LTBI, especially in
BCG vaccinated
healthcare workers
Recommendation:
Screen adults at
increased risk for
tuberculosis,
Population
description provided
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2017

Lewinsohn et al.

Evidence-based
guidelines for
diagnosing TB

Review of
evidence by task
force

23 evidenceGRADE
based
approach
recommendations
were reviewed

2017

Pai and Menzies

Evidence-based
guidelines for
diagnosing TB

Recommendations N/A
based on review
of evidence

Review of
literature

Updated diagnostic
testing
recommendations
for LTBI were
developed
Screening
recommendations
for adults without
HIV infection.
Includes
information about
TST and IGRA
tests.
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2017 Tuberculosis Project Timeline
Meet with
committee
chair

Schedule
proposal
defense

Implement
project

proposal
defense

Jan

Feb

March

Dev elop
Phenomenon
of interest
statemtent

April
Submit
first draft
capstone
proposal

May

Identify
clinic
site(s)

June

Submit
Submit
final draft to UNC
capstone IRB
proposal

July
design
clinical
protocol

August

Send
out
project
surv ey
and
collect
results

Sep

Request
oral
exam

Oct

Present
and
Defend
final
project

Nov

Dec

Submit
final
project
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APPROVAL, AND CONSENT FORM
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Date: October 17, 2017
Re: Evidence-based Tuberculosis Screening and Testing Clinical Protocol for Public
Health and Primary Care Providers: A Doctorate of Nursing Practice capstone project by
Kimberly Senn
Greetings,
I am writing to inform you about an opportunity to participate in a Doctorate of Nursing
Practice capstone project reviewing a tuberculosis testing clinical protocol. You are being
asked to complete a short online survey to provide feedback on the proposed protocol.
The survey should take no more than 10 minutes of your time. The purpose of this project
is to develop a clinical protocol for future use in both public health and primary care
settings.
This letter is being sent by the Colorado Department of Public Health and Environment
(CDPHE) TB program on behalf of the graduate student, Kimberly Senn. Your
participation in this research project is completely voluntary. You may decline altogether,
or choose not to answer specific question(s). There are no known risks to participation in
this project beyond those encountered in daily life. Your responses will remain
confidential and anonymous. Data from this research will be reported only as a collective
combined total.
The protocol and survey may be accessed through attachments and a link provided in the
e-mail (below). If you have any questions about this project, feel free to contact me via
phone or e-mail. Your assistance with this project is greatly appreciated.
Once you have reviewed the attached protocol, you may access the survey by
clicking on the link below:

TB Screening and Testing Protocol Survey
Sincerely,
Kimberly Senn, Principal Researcher
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Institutional Review Board
CONSENT FORM FOR HUMAN PARTICIPANTS IN RESEARCH
UNIVERSITY OF NORTHERN COLORADO
Project Title: Evidence-based Tuberculosis Screening and Testing Clinical Protocol for
Public Health and Primary Care Providers
Researcher: Kimberly Senn, DNP Student Phone Number: (970) 371-2887
E-mail: mill4151@bears.unco.edu
Project Advisor: Jeanette McNeill Phone Number: (970) 351-1704
E-mail: Jeanette.McNeill@unco.edu
The purpose of this doctoral capstone project is to develop a point-of-care evidence-based
clinical protocol. The protocol will assist public health, community health, and primary
care providers with screening and testing for tuberculosis (TB) in adults and children.
The protocol and link to the online survey will be e-mailed to participants with the
assistance of the Colorado Department of Public Health and Environment TB program
staff.
Participants are being asked to complete an online survey providing feedback on the
proposed protocol. Survey questions will assess the proposed protocol for effectiveness,
efficiency, and evidence-based content. Participants are asked to provide minimal
demographic information including profession (MD, RN, Administrator, etc.), work
setting, and years of work experience with TB. Participants will not be asked to provide
any personal identifying information. Data from this research will be reported only as a
collective combined total.
There are no known risks to participate in this project beyond those encountered in daily
life. Responses will remain confidential and anonymous. Benefits to the participant
include the opportunity to provide feedback on the development of a clinical protocol.
This feedback may lead to improved evidence-based clinical practice for TB screening
and testing in the future.
Participation is voluntary. You may decide not to participate in this study and if you
begin participation you may still decide to stop and withdraw at any time. Your decision
will be respected and will not result in loss of benefits to which you are otherwise
entitled. Having read the above and having had an opportunity to ask any questions,
please complete the survey if you would like to participate in this research. By
completing the survey, you will give us permission for your participation. You may keep
this form for future reference. If you have any concerns about your selection or treatment
as a research participant, please contact Sherry May, IRB Administrator, Office of
Sponsored Programs, Kepner Hall, University of Northern Colorado Greeley, CO 80639;
970-351-1910.
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Tuberculosis Screening and Testing Protocol Survey
Question

5
Strongly
Agree

Effectiveness
The TB screening tool would
increase effectiveness of TB
testing in your clinic.
The TB testing protocol will
increase effectiveness of TB
testing in your clinic.
The TB test results guidelines
will increase effectiveness of
diagnosing Latent TB Infection
in your clinic.
Evidence-based
The TB screening tool follows
the most recent evidence-based
guidelines.
The TB testing protocol
follows the most recent
evidence-based guidelines.
The TB test result guidelines
follow the most recent
evidence-based guidelines.
Efficiency
The TB screening tool would
be efficient to use in the clinic
setting.
The TB testing protocol would
be efficient to use in the clinic
setting.
The TB test result guidelines
would be efficient to use in the
clinic setting.

What would you suggest adding to
the TB screening tool?
the TB testing protocol?
the TB test result guidelines?

What would you suggest omitting from
the TB screening tool?
the TB testing protocol?
the TB test result guidelines?

4
Agree

3
Neither
Agree or
Disagree

2
Disagree

1
Strongly
Disagree
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Case examples: Please answer the following questions based utilizing the TB
screening tool, protocol and test result guidelines. Choose the test that would most
likely be offered in your clinic setting.
1. A 49-year-old adult male born in Mexico visits your clinic for a diabetes followup visit. The patient has never been tested for TB. He remembers spending time
with a family member with active TB as a child. The patient has a history of
receiving BCG vaccine as a child.
Would you recommend testing, and if so which test would you choose the TST or
IGRA?
Why would you choose this test?
2. A 4-year-old female refugee from Somalia visits your clinic. The patient’s mother
is currently being treated for active TB disease.
Which test would you choose for this patient?
Why would you choose this test?
3. A 20-year-old male college student visits the campus clinic one month after
travelling on a 3-month long medical mission trip working in a remote HIV clinic.
Would you recommend testing for TB, and if so which test would you use? TST
or IGRA?
Why would you use this test?
Additional questions:
1. In your opinion, will these screening and testing protocols increase appropriate
TB testing in the public/community health clinic setting? Yes
No
Why or why not?
2. Will these screening and testing protocols increase appropriate TB testing in the
primary care clinic setting?
Yes
No
Why or why not?
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Demographic Information:
1. What is your profession?
o
o
o
o

Registered Nurse
Physician
Medical Assistant
Other: _______________

2. What type setting do you work in (check all that apply)?
o
o
o
o
o
o

Public Health Clinic
Primary Care Clinic
Community Health Clinic
University Health Clinic
Specialty clinic _____________
Other______________

3. How much experience do you have with TB screening and testing?
o
o
o
o
o

None
0-2 years
2-5 years
5-10 years
More than 10 years

